News Scotland's TC BioPharm joins bluebird to develop next-gen CA... US cancer biotech bluebird bio has joined with TC BioPharm in a collaboration focused on gamma delta CAR-T cells.
News Scottish firm gets EU funding for 'off the shelf' cancer cel... First patients could be treated in 2019.
News JPM: AbbVie pays $650m upfront for RemeGen cancer drug AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
